Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P07333: Variant p.Ile794Thr

Macrophage colony-stimulating factor 1 receptor
Gene: CSF1R
Feedback?
Variant information Variant position: help 794 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Isoleucine (I) to Threonine (T) at position 794 (I794T, p.Ile794Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (I) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HDLS1; impairs autophosphorylation upon stimulation with CSF1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 794 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 972 The length of the canonical sequence.
Location on the sequence: help CIHRDVAARNVLLTNGHVAK I GDFGLARDIMNDSNYIVKGN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         CIHRDVAARNVLLTNGHVAKIGDFGLARDIMNDSNYIVKGN

Mouse                         CIHRDVAARNVLLTSGHVAKIGDFGLARDIMNDSNYVVKGN

Rat                           CIHRDVAARNVLLTSGHVAKIGDFGLARDIMNDSNYVVKGN

Cat                           CIHRDVAARNVLLTSGRVAKIGDFGLARDIMNDSNYIVKGN

Zebrafish                     CIHRDVAARNVLLTNSRVAKICDFGLARDIMNDSNYVVKGN
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 20 – 972 Macrophage colony-stimulating factor 1 receptor
Topological domain 539 – 972 Cytoplasmic
Domain 582 – 910 Protein kinase
Active site 778 – 778 Proton acceptor
Modified residue 809 – 809 Phosphotyrosine; by autocatalysis
Alternative sequence 307 – 972 Missing. In isoform 2.
Mutagenesis 802 – 802 D -> V. Constitutive kinase activity. Loss of inhibition by imatinib.
Mutagenesis 809 – 809 Y -> F. Reduced kinase activity. Reduced interaction with SRC, FYN and YES1.
Beta strand 791 – 794



Literature citations
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids.
Rademakers R.; Baker M.; Nicholson A.M.; Rutherford N.J.; Finch N.; Soto-Ortolaza A.; Lash J.; Wider C.; Wojtas A.; DeJesus-Hernandez M.; Adamson J.; Kouri N.; Sundal C.; Shuster E.A.; Aasly J.; MacKenzie J.; Roeber S.; Kretzschmar H.A.; Boeve B.F.; Knopman D.S.; Petersen R.C.; Cairns N.J.; Ghetti B.; Spina S.; Garbern J.; Tselis A.C.; Uitti R.; Das P.; Van Gerpen J.A.; Meschia J.F.; Levy S.; Broderick D.F.; Graff-Radford N.; Ross O.A.; Miller B.B.; Swerdlow R.H.; Dickson D.W.; Wszolek Z.K.;
Nat. Genet. 44:200-205(2012)
Cited for: VARIANTS HDLS1 774-CYS--ASN-814 DEL; 585-GLY--LYS-619 DELINS ALA; GLU-589; LYS-633; THR-766; PRO-770; ASN-775; THR-794; TYR-837; SER-849; PHE-849 DEL; PRO-868; THR-875 AND THR-878; VARIANTS HIS-710; ARG-747 AND ASP-920; CHARACTERIZATION OF VARIANTS HDLS1 LYS-633; THR-766 AND THR-875; Haploinsufficiency of CSF-1R and clinicopathologic characterization in patients with HDLS.
Konno T.; Tada M.; Tada M.; Koyama A.; Nozaki H.; Harigaya Y.; Nishimiya J.; Matsunaga A.; Yoshikura N.; Ishihara K.; Arakawa M.; Isami A.; Okazaki K.; Yokoo H.; Itoh K.; Yoneda M.; Kawamura M.; Inuzuka T.; Takahashi H.; Nishizawa M.; Onodera O.; Kakita A.; Ikeuchi T.;
Neurology 82:139-148(2014)
Cited for: VARIANTS HDLS1 ASP-765; GLU-781; THR-794 AND SER-824; CHARACTERIZATION OF VARIANTS HDLS1 ASP-765; GLU-781; THR-794 AND SER-824; AUTOPHOSPHORYLATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.